Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNV-313
- Development stage
- Unknown
- Lead developer
- Tenvie Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TNV-313 is an investigational, fully central nervous system (CNS)-penetrant small molecule inhibitor of NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3), a key regulator of innate immune signaling implicated in a broad range of inflammatory diseases. Developed by Tenvie Therapeutics, TNV-313 is designed for best-in-class brain exposure at low clinical doses to address neuroinflammation at its source without being subject to active transporter-mediated efflux. The drug is being evaluated in Phase 1 clinical trials for the treatment of neurologic, cardiometabolic, and ophthalmic diseases.
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on TNV-313.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNV-313.